Checkpoint Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
August 12, 2022 08:00 ET
|
Checkpoint Therapeutics, Inc
Positive interim results from registration-enabling study of cosibelimab in locally advanced cutaneous squamous cell carcinoma announced in June 2022 Successful completion of pre-BLA meetings in July...
Checkpoint Therapeutics Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Locally Advanced Cutaneous Squamous Cell Carcinoma
June 16, 2022 07:30 ET
|
Checkpoint Therapeutics, Inc
Objective response rate of 54.8% in patients with locally advanced cSCC, a potential 2nd indication for cosibelimabPreviously met primary endpoint in patients with metastatic cSCC; BLA submission on...
Checkpoint Therapeutics Announces Presentation of Pivotal Trial Results of Cosibelimab at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
June 06, 2022 16:30 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., June 06, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (Checkpoint) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the...
Checkpoint Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
May 19, 2022 08:30 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James...
Checkpoint Therapeutics Receives Pediatric Investigational Plan Waivers for Cosibelimab from the European Medicines Agency and U.K. Medicines & Healthcare Products Regulatory Agency
May 13, 2022 08:30 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., May 13, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (Checkpoint) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has...
Checkpoint Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Highlights
May 12, 2022 16:30 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial...
Checkpoint Therapeutics Announces Data Presentation of Pivotal Trial Results of Cosibelimab to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
April 28, 2022 08:00 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that the...
Checkpoint Therapeutics to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities
April 04, 2022 08:15 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that...
Checkpoint Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Highlights
March 28, 2022 07:30 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., March 28, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced...
Checkpoint Therapeutics to Participate in the B. Riley Securities’ Virtual Oncology Conference
January 25, 2022 16:30 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that...